Demographics and histology of the subjects and biopsies excluded in this study
| Demographics . | Percentage (n) or mean ± SD . |
|---|---|
| n | 353 |
| Donor characteristics | |
| Donor calendar age (years) | 44.6 ± 14.7 |
| Male gender, % (n) | 54.9 (195) |
| Deceased donor, % (n) | 94.6 (334) |
| Brain death/cardiac death, % (n) | 85.3 (285)/14.7 (49) |
| History of hypertension, % (n) | 20.2 (71) |
| History of diabetes mellitus, % (n) | 4.9 (14) |
| History of smoking, % (n) | 22.9 (81) |
| Body mass index (kg/m2) | 25.6 ± 4.2 |
| History of cardiovascular events, % (n) | 40.2 (142) |
| Cold ischaemia time | 14.2 ± 6.0 |
| Recipient characteristics | |
| Recipient calendar age (years) | 51.0 ± 11.6 |
| Male gender, % (n) | 56.9 (201) |
| Repeat transplantation, % (n) | 14.4 (51) |
| Post-transplant factors | |
| Delayed graft function | 16.4 (58) |
| Immunosuppressive protocol (CsA-MMF-Cs/TAC-MMF-Cs/other) | 132/198/23 |
| Presence of one or more treated acute rejection episodes after transplantation, % (n) | 16.1% (57) |
| Biopsy-proven acute cellular rejection, % (n) | 24 (85) |
| Acute antibody-mediated rejection, % (n) | 2 (6) |
| Post-transplant diabetes mellitus, % (n) | 30.2 (106) |
| Body mass index at 5 years post-transplant (kg/m2) | 25 ± 5.5 |
| Post-transplant cardiovascular events, % (n) | 27.7 (98) |
| Serum creatinine at 3 months (mg/dL) | 1.63 ± 0.49 |
| eGFR at 3 months (mL/min/1.73 m2)a | 47 ± 17.3 |
| Serum creatinine at 12 months (mg/dL) | 1.43 ± 0.41 |
| eGFR 12 at months (mL/min/1.73 m2)a | 55.0 ± 15.4 |
| Serum creatinine at 24 months (mg/dL) | 1.43 ± 0.39 |
| eGFR at 24 months (mL/min/1.73 m2)a | 55.0 ± 17.3 |
| Serum creatinine 60 months (mg/dL) | 1.47 ± 0.46 |
| eGFR at 60 months (mL/min/1.73 m2)a | 53.7.3 ± 13.6 |
| Demographics . | Percentage (n) or mean ± SD . |
|---|---|
| n | 353 |
| Donor characteristics | |
| Donor calendar age (years) | 44.6 ± 14.7 |
| Male gender, % (n) | 54.9 (195) |
| Deceased donor, % (n) | 94.6 (334) |
| Brain death/cardiac death, % (n) | 85.3 (285)/14.7 (49) |
| History of hypertension, % (n) | 20.2 (71) |
| History of diabetes mellitus, % (n) | 4.9 (14) |
| History of smoking, % (n) | 22.9 (81) |
| Body mass index (kg/m2) | 25.6 ± 4.2 |
| History of cardiovascular events, % (n) | 40.2 (142) |
| Cold ischaemia time | 14.2 ± 6.0 |
| Recipient characteristics | |
| Recipient calendar age (years) | 51.0 ± 11.6 |
| Male gender, % (n) | 56.9 (201) |
| Repeat transplantation, % (n) | 14.4 (51) |
| Post-transplant factors | |
| Delayed graft function | 16.4 (58) |
| Immunosuppressive protocol (CsA-MMF-Cs/TAC-MMF-Cs/other) | 132/198/23 |
| Presence of one or more treated acute rejection episodes after transplantation, % (n) | 16.1% (57) |
| Biopsy-proven acute cellular rejection, % (n) | 24 (85) |
| Acute antibody-mediated rejection, % (n) | 2 (6) |
| Post-transplant diabetes mellitus, % (n) | 30.2 (106) |
| Body mass index at 5 years post-transplant (kg/m2) | 25 ± 5.5 |
| Post-transplant cardiovascular events, % (n) | 27.7 (98) |
| Serum creatinine at 3 months (mg/dL) | 1.63 ± 0.49 |
| eGFR at 3 months (mL/min/1.73 m2)a | 47 ± 17.3 |
| Serum creatinine at 12 months (mg/dL) | 1.43 ± 0.41 |
| eGFR 12 at months (mL/min/1.73 m2)a | 55.0 ± 15.4 |
| Serum creatinine at 24 months (mg/dL) | 1.43 ± 0.39 |
| eGFR at 24 months (mL/min/1.73 m2)a | 55.0 ± 17.3 |
| Serum creatinine 60 months (mg/dL) | 1.47 ± 0.46 |
| eGFR at 60 months (mL/min/1.73 m2)a | 53.7.3 ± 13.6 |
Data are expressed as mean ± SD unless otherwise specified
eGFR was calculated using the MDRD formula [19, 23].
CsA, cyclosporine; Cs, corticosteroids; TAC, tacrolimus.
Demographics and histology of the subjects and biopsies excluded in this study
| Demographics . | Percentage (n) or mean ± SD . |
|---|---|
| n | 353 |
| Donor characteristics | |
| Donor calendar age (years) | 44.6 ± 14.7 |
| Male gender, % (n) | 54.9 (195) |
| Deceased donor, % (n) | 94.6 (334) |
| Brain death/cardiac death, % (n) | 85.3 (285)/14.7 (49) |
| History of hypertension, % (n) | 20.2 (71) |
| History of diabetes mellitus, % (n) | 4.9 (14) |
| History of smoking, % (n) | 22.9 (81) |
| Body mass index (kg/m2) | 25.6 ± 4.2 |
| History of cardiovascular events, % (n) | 40.2 (142) |
| Cold ischaemia time | 14.2 ± 6.0 |
| Recipient characteristics | |
| Recipient calendar age (years) | 51.0 ± 11.6 |
| Male gender, % (n) | 56.9 (201) |
| Repeat transplantation, % (n) | 14.4 (51) |
| Post-transplant factors | |
| Delayed graft function | 16.4 (58) |
| Immunosuppressive protocol (CsA-MMF-Cs/TAC-MMF-Cs/other) | 132/198/23 |
| Presence of one or more treated acute rejection episodes after transplantation, % (n) | 16.1% (57) |
| Biopsy-proven acute cellular rejection, % (n) | 24 (85) |
| Acute antibody-mediated rejection, % (n) | 2 (6) |
| Post-transplant diabetes mellitus, % (n) | 30.2 (106) |
| Body mass index at 5 years post-transplant (kg/m2) | 25 ± 5.5 |
| Post-transplant cardiovascular events, % (n) | 27.7 (98) |
| Serum creatinine at 3 months (mg/dL) | 1.63 ± 0.49 |
| eGFR at 3 months (mL/min/1.73 m2)a | 47 ± 17.3 |
| Serum creatinine at 12 months (mg/dL) | 1.43 ± 0.41 |
| eGFR 12 at months (mL/min/1.73 m2)a | 55.0 ± 15.4 |
| Serum creatinine at 24 months (mg/dL) | 1.43 ± 0.39 |
| eGFR at 24 months (mL/min/1.73 m2)a | 55.0 ± 17.3 |
| Serum creatinine 60 months (mg/dL) | 1.47 ± 0.46 |
| eGFR at 60 months (mL/min/1.73 m2)a | 53.7.3 ± 13.6 |
| Demographics . | Percentage (n) or mean ± SD . |
|---|---|
| n | 353 |
| Donor characteristics | |
| Donor calendar age (years) | 44.6 ± 14.7 |
| Male gender, % (n) | 54.9 (195) |
| Deceased donor, % (n) | 94.6 (334) |
| Brain death/cardiac death, % (n) | 85.3 (285)/14.7 (49) |
| History of hypertension, % (n) | 20.2 (71) |
| History of diabetes mellitus, % (n) | 4.9 (14) |
| History of smoking, % (n) | 22.9 (81) |
| Body mass index (kg/m2) | 25.6 ± 4.2 |
| History of cardiovascular events, % (n) | 40.2 (142) |
| Cold ischaemia time | 14.2 ± 6.0 |
| Recipient characteristics | |
| Recipient calendar age (years) | 51.0 ± 11.6 |
| Male gender, % (n) | 56.9 (201) |
| Repeat transplantation, % (n) | 14.4 (51) |
| Post-transplant factors | |
| Delayed graft function | 16.4 (58) |
| Immunosuppressive protocol (CsA-MMF-Cs/TAC-MMF-Cs/other) | 132/198/23 |
| Presence of one or more treated acute rejection episodes after transplantation, % (n) | 16.1% (57) |
| Biopsy-proven acute cellular rejection, % (n) | 24 (85) |
| Acute antibody-mediated rejection, % (n) | 2 (6) |
| Post-transplant diabetes mellitus, % (n) | 30.2 (106) |
| Body mass index at 5 years post-transplant (kg/m2) | 25 ± 5.5 |
| Post-transplant cardiovascular events, % (n) | 27.7 (98) |
| Serum creatinine at 3 months (mg/dL) | 1.63 ± 0.49 |
| eGFR at 3 months (mL/min/1.73 m2)a | 47 ± 17.3 |
| Serum creatinine at 12 months (mg/dL) | 1.43 ± 0.41 |
| eGFR 12 at months (mL/min/1.73 m2)a | 55.0 ± 15.4 |
| Serum creatinine at 24 months (mg/dL) | 1.43 ± 0.39 |
| eGFR at 24 months (mL/min/1.73 m2)a | 55.0 ± 17.3 |
| Serum creatinine 60 months (mg/dL) | 1.47 ± 0.46 |
| eGFR at 60 months (mL/min/1.73 m2)a | 53.7.3 ± 13.6 |
Data are expressed as mean ± SD unless otherwise specified
eGFR was calculated using the MDRD formula [19, 23].
CsA, cyclosporine; Cs, corticosteroids; TAC, tacrolimus.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
